• FR

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Telix And Ekalia, IBA-Framatome Joint Venture, Collaborate On US Astatine-211 Production, Securing Priority Isotope Access For TLX102-Tx Glioblastoma Pipeline

    Benzinga·10/19/2026 06:10:02
    Diffusion vocale
    • Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).
    • Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs.
    • First IBA alpha-beam cyclotron to be installed and operated at Telix's RLS Radiopharmacies site near Philadelphia, PA.
    • Leverages Telix's vertically integrated U.S. manufacturing and distribution platform, with a framework providing for the parties to evaluate additional installations at RLS sites as demand for 211At develops.